Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Gene Therapy and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SCAPER drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SCAPER Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SCAPER Products |
| Gene Delivery | SCAPER Lentivirus Full-length ORF for stable cell lines. |
View SCAPER Products |
| Benchmark Ab | Anti-SCAPER (Biosimilar standard) Recombinant positive control for validation. |
View SCAPER Products |
| Validator | SCAPER siRNA Set For knockdown verification. |
View SCAPER Products |
| Related Target A | CCNA2 Cyclin A2, critical interacting partner in cell cycle regulation. |
View CCNA2 Products |
| Related Target B | CDK2 Kinase partner in the SCAPER-Cyclin A-CDK2 axis. |
View CDK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Disruption | High-purity (>95%) recombinant SCAPER domains strictly verified by mass spec for SPR/BLI assays. |
| Intracellular Targeting (PROTACs) | Sequence-verified intracellular domains expressed in optimized hosts for accurate ubiquitination screening. |
| Lack of Reliable Controls | Recombinant benchmark antibodies included for reproducible Western Blot and IHC. |
| False Positives in Functional Assays | Validated siRNA included for strict specificity and knockdown checks. |
Live SCAPER R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The research landscape for SCAPER (S-phase cyclin A-associated protein in the endoplasmic reticulum) is rapidly evolving from exploratory genomics to active preclinical drug discovery. As an intracellular protein crucial for cell cycle progression and linked to syndromic retinitis pigmentosa, major players are shifting focus from traditional modalities to gene therapies and targeted protein degradation (PROTACs). As early-stage therapies advance, the next wave of R&D is targeting the specific disruption of the SCAPER-Cyclin A interaction axis in oncology, alongside AAV/Lentiviral-mediated gene replacement for inherited retinal diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy | Preclinical Spin-offs, Academic Hubs | Retinitis Pigmentosa | Viral Titer & Expression (Need Lentivirus for Stable Cell Lines) |
| PROTAC / Small Mol | Early-stage Biotech | Solid Tumors | PPI Assay (Need High-Purity Recombinant Proteins) |
| siRNA | Exploratory Oncology | Cell Cycle Arrest | Knockdown Validation (Need Sequence-Verified siRNA Sets) |